NCT06933056View on ClinicalTrials.gov

Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 2, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
Platelet Function and Reactivity Tests
Interventions
DRUG

Sotagliflozin (SOTA) followed by 3 drugs in a random order

400 mg/day SOTA Each drug will be given daily for 2 weeks.

DRUG

Aspirin followed by 3 drugs in a random order

81 mg/day Aspirin Each drug will be given daily for 2 weeks.

DRUG

Clopidogrel followed by 3 drugs in a random order

75 mg/day clopidogrel Each drug will be given daily for 2 weeks.

DRUG

Eliquis followed by 3 drugs in a random order

5 mg orally twice daily Eliquis Each drug will be given daily for 2 weeks.

Trial Locations (1)

48109

RECRUITING

University of Michigan, Ann Arbor

Sponsors

Collaborators (1)

Lexicon Pharmaceuticals
All Listed Sponsors
collaborator

Lexicon Pharmaceuticals

INDUSTRY

lead

University of Michigan

OTHER